Aveta Biomics Announces Abstract Acceptance for Presentation at the 2025 ASCO Annual Meeting
Aveta Biomics to present the results from Phase 2A trial of APG-157 as neoadjuvant monotherapy for head and neck cancer at ASCO 2025. BEDFORD, MA, UNITED STATES, April 30, 2025 /EINPresswire.com/ -- Aveta Biomics, a clinical-stage biotechnology …